Results 71 to 80 of about 28,236 (118)

Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. [PDF]

Exp Clin Endocrinol Diabetes
Shiber S, Sharabi A, Ayalon I, Naamany E, Grossman A, Molad Y.   +5 more
europepmc   +1 more source

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. [PDF]

BMJ Open Diabetes Res Care
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.   +16 more
europepmc   +1 more source

Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial. [PDF]

Diabetes Obes Metab
Pan C, Jiang H, Feng Y, Wang S, Zhang J, Wang Z, Zhou Y, Li F, Zhang Z, Li Y, Chen L.   +10 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. [PDF]

J Clin Invest
Farokhnia M, Tazare J, Pince CL, Bruns N, Gray JC, Lo Re V, Fiellin DA, Kranzler HR, Koob GF, Justice AC, Vendruscolo LF, Rentsch CT, Leggio L.   +12 more
europepmc   +1 more source

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase-4 Inhibitors and Serious Bleeding Events. [PDF]

Clin Pharmacol Ther
Pham Nguyen TP, Leonard CE, Brensinger CM, Bilker WB, Chung SP, Horn JR, Bogar K, Miano TA, Hennessy S.   +8 more
europepmc   +1 more source

Geospatial distribution of the adoption of dipeptidyl-peptidase-4 inhibitors for type 2 diabetes among Medicare beneficiaries. [PDF]

Spat Spatiotemporal Epidemiol
Cordes J, Glynn RJ, Walker AM, Schneeweiss SS.   +3 more
europepmc   +1 more source

The Therapeutic Potential of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Peripheral Neuropathy. [PDF]

Diabetes Ther
Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. [PDF]

Diabetes Obes Metab
Chen MH, Lin LY, Hung TY, Lin TC, Li CY, Lin TH, Chen YH, Liou JT, Wang MT.   +8 more
europepmc   +1 more source